New rapid COVID-19 test the result of university-industry partnership

A partnership between UC Davis and Maurice J. Gallagher, Jr., chairman and CEO of Allegiant Travel Company, has led to a 20-minute COVID-19 test. The method pairs a mass spectrometer with a powerful machine-learning platform to detect SARS-CoV-2 in nasal swabs. A recent study published in Nature Scientific Reports shows the test to be 98.3% accurate for positive COVID-19 tests and 96% for negative tests.

CAP Opens PD-L1 Lung Tumor Testing Guideline for Public Comment

The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer (NSCLC) who are being considered for immunooncology therapy.

CAP releases 2020 edition of Laboratory Accreditation Program checklists used for inspection of medical laboratories

The College of American Pathologists (CAP) released the 2020 edition of its Laboratory Accreditation Program checklists on June 4, 2020. CAP inspectors use the checklists, with approximately 3,000 requirements, during inspections to ensure laboratories comply with the Centers for Medicare and Medicaid Services (CMS) regulations and achieve accreditation.

Dr. Maurice O’Gorman to Speak on AAAS Webinar about Immune System Monitoring to Combat COVID-19

Dr. O’Gorman, Chief of Laboratory Medicine at CHLA and Professor of Pathology and Pediatrics at the Keck School of Medicine of USC, is an expert in immune monitoring and flow cytometry assays for the assessment of immune dysfunction. During this webinar, Dr. O’Gorman will discuss early results from labs around the world that have begun measuring CD4 and CD8 T-cell levels in peripheral blood as potential biomarkers for the prognosis of patients with COVID-19.

Mount Sinai’s Blood Test to Detect Antibodies to COVID-19 Receives Emergency Use Authorization From U.S. Food and Drug Administration

Today, the Mount Sinai Laboratory (MSL), Center for Clinical Laboratories received emergency use authorization from the U.S. Food and Drug Administration (FDA) for an antibody test that was developed, validated, and launched at Mount Sinai by a team of internationally renowned researchers and clinicians of the Icahn School of Medicine at Mount Sinai. This test detects the presence or absence of antibodies to SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) and importantly, may also be used to identify positive specimens with an antibody titer (level) up to a dilution of 1:2880 for the identification of individuals with higher antibody titers.

The Best in Pathology, Laboratory Quality, Proficiency Testing, Technology & Patient Safety

The College of American Pathologists Releases List of Longest Accredited Laboratories in U.S. Northfield, IL (June 24, 2019) This week, the College of American Pathologists (CAP) released a list of its longest accredited laboratories in the United States. These 41…